http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014102362-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 |
| filingDate | 2012-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014102362-A |
| titleOfInvention | ANTITROMBOTIC COMPOUNDS |
| abstract | 1. Essentially a pure compound of formula IIA, a salt thereof, where the * symbol marks a chiral carbon center having the absolute stereochemical configuration (S, S). 2. A compound according to claim 1, wherein said compound is isolated in a form substantially free of its other chiral isomers of formula IIB, where the symbol * marks a chiral carbon center, and structural isomers of formulas VI and / or VII.3. The compound of formula IIA according to claim 2, wherein the other isomers of formulas IIB, VI, or VII individually or collectively comprise less than 10% by weight. A compound of formula IIA according to claim 2, wherein the other isomers of formulas IIB, VI and / or VII comprise less than 3% by weight. A compound of formula IIA according to claim 2, wherein the other isomers of formulas IIB, VI and / or VII are less than 1.0% by weight. The compound of formula IIA according to claim 1, wherein said salt is selected from the group consisting of a hydrosulfate salt, methanesulfonate or benzenesulfonate. Isomerically pure methyl- (7aS, 2′S) -2- (2-chlorophenyl) -2- (2,4,5,6,7,7a-hexahydrothieno [3,2-c] -5-pyridin-2- he) acetate or its salts, solvates, complexes. 8. Methyl- (7aS, 2′S) -2- (2-chlorophenyl) -2- (2,4,5,6,7,7a-hexahydrothieno [3,2-c] -5-pyridin-2-one hydrosulfate ) acetate. 9. Methyl- (7aS, 2′S) -2- (2-chlorophenyl) -2- (2,4,5,6,7,7a-hexahydrothieno [3,2-c] -5-pyridin-2-one methanesulfonate ) acetate. 10. Methyl- (7aS, 2′S) -2- (2-chlorophenyl) -2- (2,4,5,6,7,7a-hexahydrothieno [3,2-c] -5-pyridin-2-one benzene sulfonate ) acetate. 11. Methyl- (7aS, 2′S) / (7aR, 2′S) -2- (2-chlorophenyl) -2- (2,4,5,6,7,7a-hexahydrothieno [3.2-c] hydrochloride -5-pyridin-2-one) acetate. 12. A pharmaceutical composition comprising an isolated compound of formula IIA or a pharmaceutically acceptable salt thereof (one or more) and optionally containing pharmaceutical excipients. The pharmaceutical composition of claim 12, wherein the compound of formula IIA pre |
| priorityDate | 2011-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.